IC
KNSA icon

Ikarian Capital’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Ikarian Capital’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-59,422
Closed -$677K – 217
2021
Q3 		$677K Buy
+59,422
New +$774K 0.05% 175
2021
Q2 		– Sell
-51,273
Closed -$949K – 249
2021
Q1 		$949K Sell
51,273
-50,000
-49% -$1.02M 0.03% 238
2020
Q4 		$1.79M Sell
101,273
-241,725
-70% -$4.25M 0.08% 160
2020
Q3 		$5.25M Buy
342,998
+314,724
+1,113% +$5.91M 0.38% 67
2020
Q2 		$720K Sell
28,274
-330,650
-92% -$6.91M 0.06% 127
2020
Q1 		$5.56M Buy
+358,924
New +$5.62M 0.42% 58

Other funds holding KNSA

PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Ikarian Capital's KNSA Position: Q4 2021 in Review

Ikarian Capital sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2021, closing a stake of 59,422 shares — an estimated $677K sold.

Ikarian Capital first reported a position in KNSA in Q1 2020 and held it in 6 quarters. The position peaked at $5.56M in Q1 2020. 103 funds tracked by Wall St. Rank hold KNSA as of Q4 2021.

  • Ikarian Capital reported no remaining Kiniksa Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Ikarian Capital sold 59,422 Kiniksa Pharmaceuticals shares in Q4 2021, an estimated $677K.
  • Ikarian Capital first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Ikarian Capital's Kiniksa Pharmaceuticals position peaked at $5.56M in Q1 2020.
  • 103 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2021.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.